Regeneron Pharmaceuticals v Kymab Limited

Link copied
Case Copied 52 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Regeneron Pharmaceuticals v Kymab Limited [2017] APO 37

Patent Application:                   2011266843

Title:Animal models and therapeutic molecules

Patent Applicant:  Kymab Limited

Opponent:  Regeneron Pharmaceuticals

Delegate:  Dr B. Akhurst

Decision Date:  19 July 2017

Hearing Date:  Written submissions filed on 4, 18 and 26 April 2017.

Catchwords:  PATENTS – opposition under section 104 – allowability under section 102(2) considered – opposition successful – amendment refused – no award of costs.

Representation:  Patent attorney for the applicant: Griffith Hack.

Patent attorney for the opponent: FB Rice.

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                   2011266843

Title:Animal models and therapeutic molecules

Patent Applicant:  Kymab Limited

Date of Decision:  19 July 2017

DECISION

I allow the amendment to the statement of grounds and particulars requested by Regeneron.

The opposition is successful and I refuse the amendments.

I make no award of costs.

REASONS FOR DECISION

Background

  1. Patent application 2011266843 was filed by Kymab Limited (Kymab) on 7 January 2011 under the provisions of the PCT, claiming an earliest priority date of 17 June 2010.  The application was advertised as accepted on 30 April 2015.

  2. Regeneron Pharmaceuticals, Inc. (Regeneron) filed a Notice of Opposition to grant of a patent on 30 July 2015 and a statement of grounds and particulars (SGP) on 30 October 2015.  Evidence in support, answer and reply in the section 59 opposition was completed by 4 July 2016.      

  3. Subsequently, Kymab proposed amendments to the specification under section 104 on 3 August 2016, 7 September 2016 and 25 October 2016.  The grant of leave to amend was advertised under reg. 10.5(2) on 8 December 2016.  On 8 February 2017, Regeneron filed a Notice of Opposition to allowance of the amendments, followed by a SGP on 8 March 2017.  Neither party sought to file evidence in the s 104 opposition, and the matter was set for a hearing by written submissions.

  4. On 4 April 2017, Regeneron requested amendments to its SGP in the s104 opposition and advised, in effect, that it relied on the particulars in the original and subsequently filed SGP for its written submissions in the s104 opposition.  

  5. On 18 April 2017, Kymab filed submissions in answer to the matters particularised in the SGP and proposed amendments, and confirmed on 12 May 2017 that it did not object to the SGP amendment request.  In the circumstances, I consider it reasonable to allow Regeneron’s request to amend the SGP in the s104 opposition. 

  6. Regeneron filed submissions in reply on 26 April 2017.

  7. This decision relates only to Regeneron’s opposition to Kymab’s request to amend the specification under section 104.   

    Issue estoppel

  8. Kymab’s submissions for the hearing are substantially that, in deciding this matter, I should disregard Regeneron’s submissions where they had already been considered by the examining delegate who granted leave to amend the specification.  However, administrative decisions by the Commissioner do not give rise to an issue estoppel and consequently I am not estopped from deciding all of the matters raised in…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Regeneron Pharmaceuticals v Kymab Limited and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2017] APO 37
Decision Date

CaseChat Overview and Summary

This case involved an opposition by Regeneron Pharmaceuticals, Inc. (Regeneron) to the grant of patent application 2011266843, filed by Kymab Limited (Kymab). The application, titled "Animal models and therapeutic molecules" related to non-human animals and cells containing exogenous human immunoglobulin gene DNA, methods for their production and antibodies and antibody chains produced by such animals. Kymab had proposed amendments to the specification and Regeneron opposed the grant of these amendments. The dispute was heard by Dr B. Akhurst, a Delegate of the Commissioner of Patents. The key legal issues were whether the amendments to the specification complied with subsection 102(2) of the Patents Act 1990 (the Act) and whether the amendments were allowable under subsection 102(2)(a) and 102(2)(b). The court found that the opposition was successful. The proposed claim 33 as amended lacked clarity and did not comply with the requirements of subsection 102(2) of the Act. The amendments will be refused. The court made no award of costs.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.